Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

@article{Tefferi2007ProposalsAR,
  title={Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.},
  author={A. Tefferi and J. Thiele and A. Orazi and H. Kvasnicka and T. Barbui and C. Hanson and G. Barosi and S. Verstovsek and G. Birgegard and R. Mesa and J. Reilly and H. Gisslinger and A. Vannucchi and F. Cervantes and G. Finazzi and R. Hoffman and D. Gilliland and C. Bloomfield and J. Vardiman},
  journal={Blood},
  year={2007},
  volume={110 4},
  pages={
          1092-7
        }
}
  • A. Tefferi, J. Thiele, +16 authors J. Vardiman
  • Published 2007
  • Medicine
  • Blood
  • The Janus kinase 2 mutation, JAK2617V>F, is myeloid neoplasm-specific; its presence excludes secondary polycythemia, thrombocytosis, or bone marrow fibrosis from other causes. Furthermore, JAK2617V>F or a JAK2 exon 12 mutation is present in virtually all patients with polycythemia vera (PV), whereas JAK2617V>F also occurs in approximately half of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Therefore, JAK2 mutation screening holds the promise of a decisive… CONTINUE READING
    829 Citations

    References

    SHOWING 1-10 OF 58 REFERENCES
    Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    • 3,101
    • PDF